AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19356393
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release cyclobenzaprine tablet (20 mg) with high fat meal
Trial: 19356393
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release cyclobenzaprine tablet (10 mg)
Trial: 17239355
Drug: D-amphetamine 10
RxNorm normalized name: amphetamine / dextroamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-amphetamine 10 mg
Trial: 9039834
Drug: Beta-carotene supplementation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation (30 mg betaC/d)
Trial: 8174049
Drug: 25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/kg etidronate disodium for 24 hours
Trial: 8174049
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg etidronate disodium for 24 hours
Trial: 29540217
Drug: Linagliptin once
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Linagliptin once daily
Trial: 26439936
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of iodopovidone
Trial: 2511911
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg twice daily plus Atenolol 50 mg twice daily
Trial: 2511911
Drug: Nifedipine 40
RxNorm normalized name: nifedipine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 40 mg twice daily plus Atenolol 50 mg twice daily
Trial: 12618533
Drug: Low-dose ACTH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ACTH
Trial: 29908688
Drug: Honey (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honey (70 g per day)
Trial: 29908688
Drug: Sucrose (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (70 g per day)
Trial: 27703294
Drug: Lisinopril/Hydrochlorothiazide
RxNorm normalized name: lisinopril/hydrochlorothiazide 20 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril/Hydrochlorothiazide
Trial: 24779731
Drug: Two drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two drug combinations
Trial: 21029610
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: osteoform 1000 mg/d + alfacalcidol 0.25 µg/bid orally
Trial: 21029610
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: osteoform 1000 mg/d + alfacalcidol 0.25 µg/bid + tibolone 1.25 mg/d orally
Trial: 21029610
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: osteoform 1000 mg/d + alfacalcidol 0.25 µg/bid + bisphosphonates 70 mg/w orally
Trial: 15960573
Drug: Luteal phase
RxNorm normalized name: Nuphar lutea leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteal phase dosing of escitalopram (10-20 mg/day)
Trial: 15960573
Drug: Symptom-onset dosing
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom-onset dosing of escitalopram (10-20 mg/day)
Trial: 10596559
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine (0.15 mg infusion 15 minutes before operation)
Trial: 10596559
Drug: Intramuscular clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular clonidine (0.15 mg 60-90 minutes before operation)
Trial: 1781761
Drug: Betamethasone dipropionate
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone dipropionate cream 0.05% applied twice daily
Trial: 29577512
Drug: Cognitive remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive remediation therapy (CRT) in addition to standard treatment
Trial: 26943500
Drug: Supplementary oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementary oral immunonutrition (IN) (Oral Impact®, Nestlé) to reach a goal of 1.5 g protein/kg BW, administered for seven days before surgery.
Trial: 26943500
Drug: Supplementary oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementary oral immunonutrition (IN) (Oral Impact®, Nestlé)
Trial: 11206234
Drug: Azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine nasal spray (two sprays per nostril twice daily, 1.1 mg/day)
Trial: 2645030
Drug: 5 per
RxNorm normalized name: 25 Person ANSI KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 per cent acyclovir ointment
Trial: 23819410
Drug: Combined physiotherapeutic
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined physiotherapeutic treatment including collar zone massage, orthotraction therapy, and soft cervical collar
Trial: 8345288
Drug: Loteprednol etabonate
RxNorm normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loteprednol etabonate (LE) 0.5% suspension, 1 drop 4 times daily for 42 days
Trial: 8345288
Drug: Prednisolone acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone acetate (PA) 1.0%, 1 drop 4 times daily for 42 days
Trial: 3731678
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg PPA (sustained-release preparation)
Trial: 29861230
Drug: Instrument-assisted soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instrument-assisted soft tissue mobilization (IASTM) treatments (six treatments over three weeks)
Trial: 25284194
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg of sodium selenite once daily for 365 consecutive days
Trial: 20814325
Drug: Osmotic-release oral
RxNorm normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Osmotic-release oral system methylphenidate (OROS MPH)
Trial: 20814325
Drug: Methylphenidate transdermal
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate transdermal system (MTS) with dose escalation to 30 mg per 9 hours
Trial: 20814325
Drug: Osmotic-release oral
RxNorm normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Osmotic-release oral system methylphenidate (OROS MPH) with dose escalation to 54 mg
Trial: 20814325
Drug: Methylphenidate transdermal
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate transdermal system (MTS) and OROS MPH
Trial: 17650795
Drug: Fuzheng Jiedu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzheng Jiedu Granule (FJG) plus Western medicine
Trial: 14634543
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg transdermal estradiol
Trial: 14634543
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg transdermal estradiol
Trial: 8530994
Drug: Real low-level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real low-level laser (LLL) treatment (4 x 6 J per treatment, total of 20 treatments)
Trial: 8530994
Drug: Placebo low-level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo low-level laser treatment
Trial: 8530994
Drug: Real low-level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real low-level laser (LLL) treatment
Trial: 1824798
Drug: High-dose medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose medroxyprogesterone acetate (HD MAP) 1,000 mg b.i.d. p.o.
Trial: 1824798
Drug: High-dose medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose medroxyprogesterone acetate (HD MAP)
Trial: 1824798
Drug: High-dose medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose medroxyprogesterone acetate (HD MAP) and Oophorectomy (OPX)
Trial: 4087291
Drug: Riboflavin 5
RxNorm normalized name: riboflavin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riboflavin 5 mg dose
Trial: 4087291
Drug: Larger doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larger doses of riboflavin
Trial: 24753478
Drug: Nonivamide treatment
RxNorm normalized name: Nonivamide
DrugBank: Nonivamide (DB11324)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonivamide treatment (NT) - 0.15 mg nonivamide added to 75 g glucose in 300 mL water
Trial: 24753478
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (CT) - 75 g glucose in 300 mL water
Trial: 24753478
Drug: Nonivamide treatment
RxNorm normalized name: Nonivamide
DrugBank: Nonivamide (DB11324)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonivamide treatment (NT)
Trial: 23536015
Drug: Breast cancer
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast cancer survivors treated with chemotherapy
Trial: 19887889
Drug: Supportive-experiential group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive-experiential group therapy
Trial: 11447732
Drug: GnRH-agonist leuprorelin
RxNorm normalized name: leuprorelin
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH-agonist leuprorelin acetate depot (LAD) 3.75 mg subcutaneously per month
Trial: 11447732
Drug: Gestagen lynestrenol
RxNorm normalized name: lynestrenol
DrugBank: Lynestrenol (DB12474)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestagen lynestrenol (LYN) 5 mg orally twice per day
Trial: 8033761
Drug: Naltrexone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (100 mg on Days 1 and 3, and 150 mg on Day 5)
Trial: 1111465
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (intermittent melphalan and prednisone)
Trial: 25046944
Drug: Pinaverium Bromide
RxNorm normalized name: pinaverium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinaverium Bromide Tablet
Trial: 15661459
Drug: Nefopam 80
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam 80 mg continuous infusion
Trial: 15661459
Drug: Nefopam 120
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam 120 mg continuous infusion
Trial: 15661459
Drug: Placebo continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo continuous infusion
Trial: 12878920
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg daily) + Cognitive Behavioral Therapy (CBT)
Trial: 12878920
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg daily) + Supportive Therapy
Trial: 12878920
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Supportive Therapy
Trial: 9988404
Drug: Cabergoline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (0.5 mg orally every week)
Trial: 7487796
Drug: 75-200 mg
RxNorm normalized name: carbidopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75-200 mg dosage range of tricyclic antidepressant
Trial: 7487796
Drug: 75-425 mg
RxNorm normalized name: urea 425 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75-425 mg dosage range of tricyclic antidepressant
Trial: 31714584
Drug: ATRA plus
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATRA plus chemotherapy (CT)
Trial: 29344773
Drug: Hybrid intervention
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid intervention (combination of online sexual health program and supplemental class lessons)
Trial: 24131664
Drug: Epidural oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural oxycodone (0.1 mg kg(‐1))
Trial: 24131664
Drug: Intravenous oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous oxycodone (0.1 mg kg(‐1))
Trial: 22735432
Drug: Hormone levels
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone levels and metabolic syndrome components
Trial: 16089141
Drug: Shenqi fuzheng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenqi fuzheng injection (SFI)
Trial: 16089141
Drug: No Shenqi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Shenqi fuzheng injection (SFI)
Trial: 22568921
Drug: Linezolid 600
RxNorm normalized name: linezolid 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid 600 mg IV or orally every 12 h
Trial: 22568921
Drug: Vancomycin 15
RxNorm normalized name: vancomycin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 15 mg/kg or 1 g IV every 12 h
Trial: 19293413
Drug: Pactimibe 100
RxNorm normalized name: Pactimibe
DrugBank: Pactimibe (DB12971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pactimibe 100 mg/d
Trial: 12507242
Drug: 3i threaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3i threaded implants (self-tapping, ICE, Osseotite)
Trial: 8445432
Drug: Intrathecal methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal methotrexate (10 mg) twice weekly
Trial: 8445432
Drug: Thiotepa (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiotepa (10 mg) twice weekly
Trial: 30346225
Drug: Energy-dense enteral
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy-dense enteral nutrition (1.5 kcal/ml)
Trial: 27060053
Drug: Phosphodiesterase type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphodiesterase type 5 inhibitor
Trial: 16701078
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) for 3 months
Trial: 21927686
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion at the rate of 0.17 µg/kg/min
Trial: 7793548
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of bupivacaine 0.125% with diamorphine 0.0025%
Trial: 7793548
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of bupivacaine 0.062% with diamorphine 0.0025%
Trial: 7793548
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of bupivacaine 0.031% with diamorphine 0.0025%
Trial: 7793548
Drug: All bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All bupivacaine infusions
Trial: 2569488
Drug: Metronidazole (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (0.6 g/day)
Trial: 2569488
Drug: Sulfasalazine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (2 g/day)
Trial: 19550340
Drug: Dexmedetomidine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (loading dose 1 microg/kg for 10 min followed by infusion of 0.2-0.7 microg/kg/h)
Trial: 19550340
Drug: Midazolam (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (bolus dose 0.04 mg/kg followed by infusion of 0.04-0.08 mg/kg/h)
Trial: 9692106
Drug: Capsaicin inhalation
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin inhalation after combined beta- and atropinic blockade in mild asthmatics
Trial: 9692106
Drug: Capsaicin inhalation
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin inhalation in nocturnal asthmatics after atropinic blockade alone
Trial: 9692106
Drug: Capsaicin inhalation
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin inhalation in normal subjects after atropine plus propranolol
Trial: 3653590
Drug: Diltiazem 60
RxNorm normalized name: DILTIAZEM 60MG 12HR CAP,SA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 60 mg tid
Trial: 30138085
Drug: HDMTX (Berlin-Frankfurt-Muenster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDMTX (Berlin-Frankfurt-Muenster high-dose intravenous MTX regimen)
Trial: 24024826
Drug: Stepped care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped care intervention including self-help material, chat forum, FAQ section, and cognitive behavioral therapy (CBT) administered by a personal therapist if symptoms persist.
Trial: 19159941
Drug: Post-tonsillectomy injection
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-tonsillectomy injection of bupivacaine
Trial: 10669363
Drug: Trivalent live
RxNorm normalized name: influenza vaccine trivalent live 2024-2025 (2 yrs-49 yrs) 10exp6.5-7.5 FF unit/0.2 mL NASAL NASAL SPRAY SYRINGE (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent live attenuated influenza vaccine (LAIV)
Trial: 9107443
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy 0.5/120 mg
Trial: 9107443
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy 0.5/180 mg
Trial: 9107443
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy 2/180 mg
Trial: 9107443
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy 2/240 mg
Trial: 9107443
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy 8/240 mg
Trial: 1315560
Drug: Renin inhibitor
RxNorm normalized name: Renin inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin inhibitor CGP 38560A (125 micrograms kg‐1)
Trial: 1315560
Drug: Renin inhibitor
RxNorm normalized name: Renin inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin inhibitor CGP 38560A (250 micrograms kg‐1)
Trial: 1315560
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor lisinopril (20 mg)
Trial: 30957391
Drug: Clopidogrel-aspirin dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel-aspirin dual treatment
Trial: 29871668
Drug: Frequent, rapid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequent, rapid, on-site testing and treatment (TnT)
Trial: 26740254
Drug: High-dose black
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose black raspberry (2500 mg/d)
Trial: 26740254
Drug: Moderate-dose black
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose black raspberry (1500 mg/d)
Trial: 24699059
Drug: Intravenous tissue‐type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue‐type plasminogen activator followed by endovascular treatment
Trial: 24699059
Drug: Intravenous tissue‐type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue‐type plasminogen activator alone
Trial: 17185020
Drug: Idursulfase at
RxNorm normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idursulfase at 0.15 mg/kg infused every other week
Trial: 17185020
Drug: Idursulfase at
RxNorm normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idursulfase at 0.5 mg/kg
Trial: 17185020
Drug: Idursulfase at
RxNorm normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idursulfase at 1.5 mg/kg
Trial: 17185020
Drug: Idursulfase (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idursulfase (all doses)
Trial: 8122594
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of dipyridamole intravenously over 1 hour, starting immediately before the procedure (group 1)
Trial: 8122594
Drug: Dipyridamole administered
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipyridamole administered before the procedure (group 2)
Trial: 8122594
Drug: No dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No dipyridamole administered (group 3)
Trial: 983794
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g niceritrol given three times daily (1 g X 3)